Eupraxia Pharmaceuticals (EPRX) Profit After Tax (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Profit After Tax of $12.7 million for Q1 2026, up 87.0% year-over-year from $6.8 million in Q1 2025, and up 175.68% quarter-over-quarter from -$16.7 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Profit After Tax (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Profit After Tax for 4 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 87.0% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $11.1 million (up 1361.34% YoY), while the FY2025 annual figure was -$38.6 million, down 48.9% from the prior year.
- Profit After Tax grew to $12.7 million in Q1 2026 per EPRX's latest filing, from -$16.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $12.7 million in Q1 2026 and bottomed at -$46.6 million in Q4 2023.
- Historically, Profit After Tax has averaged -$1.7 million across 4 years, with a median of $6.1 million in 2024.
- On a YoY basis, Profit After Tax climbed as much as 206.31% in 2025 and fell as far as 116.71% in 2025.
- Eupraxia Pharmaceuticals' Profit After Tax stood at -$46.6 million in 2023, then soared by 83.43% to -$7.7 million in 2024, then sank by 116.71% to -$16.7 million in 2025, then surged by 175.68% to $12.7 million in 2026.
- Business Quant data shows EPRX's Profit After Tax at $12.7 million in Q1 2026, -$16.7 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | -12.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.65 Mn |
| Dec 31, 2025 | -16.72 Mn |
| Sep 30, 2025 | 6.37 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 6.77 Mn |
| Dec 31, 2024 | -7.72 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 6.16 Mn |
| Dec 31, 2023 | -46.58 Mn |
| Sep 30, 2023 | -4.90 Mn |
| Jun 30, 2023 | 9.51 Mn |
| Mar 31, 2023 | 3.96 Mn |